btk and plcg2 mutations in cll patients taking ibrutinib
Published 4 years ago • 156 plays • Length 2:41Download video MP4
Download video MP3
Similar videos
-
2:24
prevalence of btk and plcγ2 mutations in cll relapsing under ibrutinib
-
3:12
btk and bcl2 inhibitor resistance in cll: session highlights
-
1:24
sequencing of btk inhibitors in cll
-
2:53
considering the sequencing of covalent and non-covalent btk inhibitors in cll
-
2:37
resistance to acalabrutinib in cll is mediated by btk mutations
-
4:17
how to approach r/r cll
-
2:29
the long-term efficacy of acalabrutinib-based regimens in patients with cll
-
5:48
chronic lymphocytic leukaemia (cll) through the lens
-
2:25
btk and bcl-2 inhibitor combination therapies in cll
-
2:36
changing epigenetic markers in cll patients on ibrutinib
-
1:37
causes & management of ibrutinib discontinuation in cll
-
1:05
btk degraders in the treatment of cll
-
1:44
the impact of acalabrutinib treatment by line of therapy in patients with cll
-
2:02
the benefits of next-generation btk inhibitors in cll
-
1:26
combining btk and bcl-2 inhibitors for the treatment of cll
-
1:10
the role of next-generation btk inhibitors in the treatment of cll
-
1:53
clinical outcomes of btki ven treatment in cll/sll: double-exposed vs double-refractory patients
-
1:19
outcomes of cll patients following treatment with a covalent btk and bcl2 inhibitor
-
2:49
assessing parameters and standardising biomarker detection in cll
-
3:11
btk inhibitors for cll: acalabrutinib vs ibrutinib
-
2:53
btk inhibitors in cll
-
2:51
key btk inhibitor trials for the initial treatment of cll